Statins and atrial fibrillation – mini-review on recent evidence

Bożena Sosnowska¹,B,D, Maciej Banach¹-2,A,E-F

A - Research concept and design, B - Collection and/or assembly of data, C - Data analysis and interpretation, D - Writing the article, E - Critical revision of the article, F - Final approval of article

1 Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland
2 Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

Address for correspondence:
Bożena Sosnowska, Medical University of Lodz, Poland
email: bozena.sosnowska@umed.lodz.pl
Prof. Maciej Banach, MD, PhD, FNLA, FAHA, FESC; FASA, Head, Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113; 90-549 Lodz, Poland. Phone: +48 42 639 37 71; Fax: +48 42 639 37 71; E-mail: maciejbanach@aol.co.uk

Received: 27.12.2016
Accepted: 27.12.2016

Key words:
statins, atrial fibrillation, cardiac surgery, prevention

Abstract

Introduction

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, and it is associated with higher morbidity and mortality. However, treatment options for AF are still limited and often not effective. Studies have indicated that statins might be associated with a decreased risk of occurrence or recurrence of AF. The following review summarizes the key findings of the recently published studies.

Statins in postoperative AF

AF is the most common postoperative complication after cardiothoracic and non-cardiothoracic surgery (Banach et al. 2007 & 2010). Frequency of postoperative atrial fibrillation (POAF) despite implementation of several drug therapies might reach even 65% (Mathew et al., 2004; Patti et al., 2006). The mechanism for the occurrence of postoperative AF has been postulated to be associated with increased levels of systemic inflammatory markers and oxidative stress parameters preoperatively (Aviles et al., 2003). Several studies have indicated an association between AF and various inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP) and TC (Guo et al., 2012). Other studies have also suggested a role of preoperative arrhythmias as a predictor of POAF (Banach et al. 2007).

Statins are the most effective drugs to treat hypercholesterolemia (Hobbs et al. 2016). Available studies indicated that statin therapy might be effective in protecting against AF in acute coronary syndrome (ACS) (Zhou et al., 2013) and coronary artery disease (CAD) (Zhou et al., 2013a), but the strongest evidence for AF prevention by statin intake is in post-cardiac surgery patients (Kuhn et al., 2014).
The mechanism whereby statin might prevent AF has not been fully clarified, but it might involve the pleiotropic effects of anti-inflammatory and antioxidant activities, prevention of endothelial dysfunction and neurohumoral activation (Adam et al., 2008).

Most studies showing a decrease in POAF associated with statin use have been conducted in patients undergoing cardiac surgery (Mariscalco et al., 2007; Kourliouros et al., 2008; Patti et al., 2006). A recent meta-analysis based on the results of 15 clinical studies carried out on 9369 patients of whom 5598 (59.75%) used statins and 3771 (49.25%) did not receive them also confirmed the beneficial role of statin therapy prior to coronary artery bypass grafting (CABG) (Bokeriya et al., 2016). Statin treatment decreased the frequency of AF soon after coronary bypass surgery (OR 0.481 at 95% CI 0.435-0.672; p < 0.001) and decreased the frequency of cerebral circulation disorders (OR 0.067 at 95% CI 0.037-0.121; p < 0.001) (Bokeriya et al., 2016). Efficacy of preoperative statin therapy in patients who underwent CABG was also confirmed in a retrospective study by Bokeria et al. (2016).

In other types of cardiac surgery, such as isolated cardiac valve surgery, Boleta and Kong (2015) indicated that pre-operative statin use was not associated with a decreased incidence of POAF. The results of this retrospective study of 244 adults may be associated with the fact that the duration of preoperative statin use and the statin dose were unknown and were not included in the analysis. Moreover, patients after isolated cardiac valve surgery may undergo a different inflammatory and oxidative response than patients after reperfusion surgery (Boleta and Kong 2015).

A recent meta-analysis (Razaei et al., 2016), which included 12 randomized controlled trials (RCTs) involving 1116 patients, indicated that perioperative statin therapy in statin-naive patients with sinus rhythm undergoing cardiac surgery led to a decrease in the development of POAF, the hospital length of stay (LOS), and the CRP level. Moreover, it was found that the beneficial effects on AF occurrence and CRP level were more marked in patients receiving atorvastatin compared to other statins (Razaei et al., 2016).

In patients undergoing non-transplant cardiac surgery, pre-operative use of statins has proven to be beneficial in many studies. However, data on the influence of pre-operative statin therapy in heart transplant surgery are lacking. A recent retrospective study on the influence of pre-transplant statin treatment on clinical outcomes after heart transplantation indicated that pre-operative statin therapy does not seem to influence the risk of mortality or early POAF after heart transplantation (Krishnan et al., 2016). These are preliminary findings, which should be confirmed by further large-scale prospective clinical studies.

Chronic kidney disease (CKD) can greatly increase the risk of developing AF (Alonso et al., 2011). Previous studies indicated no beneficial effect on reduction of any CV event of statin therapy in dialysis patients (Wanner et al., 2005, Barylski et al. 2013). Studies of Ho et al. (2015) showed that statin therapy was associated with lower risk of newly diagnosed AF in dialysis patients. The authors of that study observed a significant dose-dependent inverse association between new-onset AF and statin use for total accumulated doses. The protective effect was especially seen among patients who received the highest total statin dosage.

**Type and dose of statin in atrial fibrillation**

The exact difference of different types of statin in preventing POAF occurrence has not been sufficiently investigated. Atorvastatin is a highly effective statin and is the most studied statin in relation to AF (Fauchier et al., 2013; Yang et al., 2014). The influence of preoperative treatment of atorvastatin before cardiac surgery on POAF reduction is, however, conflicting. There are studies which confirm the benefit of atorvastatin in AF reduction (Patti et al., 2006), but there are also studies with the opposite results (Tamura et al., 2010). Recently Elgendy et al. (2015) elucidated in a metaanalysis of 12 RCTs postoperative reduction in AF occurrence with atorvastatin (lipophilic statin) 20 to 40 mg but not with rosuvastatin (hydrophilic statin) in patients who underwent isolated CABG. The result from this study suggested that earlier initiation of statin therapy before CABG might increase the reduction of the postoperative AF risk.

Advanced age is indicated as a major risk factor for the development POAF after cardiac surgery (Mathew at al., 1996). Data on whether pre-operative statin therapy is beneficial in advanced age patients on POAF occurrence is lacking. Recently, Kunt et al. (2015) demonstrated no influence of pre-treatment with atorvastatin in doses of 20 and 40 mg on AF reduction after cardiac surgery in patients aged over seventy years. The authors also found no association between dose and duration of statin therapy for the development of POAF (Kunt et al., 2015).

Results concerning the influence of the dose of atorvastatin on POAF occurrence are also conflicting. Some studies indicate that higher dose statins have a greater preventive effect, in comparison to low-dose statins (Lertsburapa et al., 2008), while others report opposite findings (Wang et al., 2011). There are also studies which found equal benefits of high and low dosage of statins in prevention of AF (Karimi et al., 2012).

Pierri et al. (2016) studied the influence of seven-day preoperative treatment with two different dosages of atorvastatin on the incidence of POAF in 212 patients undergoing elective first-time on-pump CABG. The authors reported that comparing treatment with 80 mg and 40 mg of atorvastatin, the higher dosage group had lower incidence of POAF but the difference was not significant. Moreover, there was no significant difference between the treatment of these two dosages of statin and the level of hsCRP and interleukin-6 (IL-6) at 12 and 24 h. The recent study of Zheng et al. (2016) indicated that perioperative rosuvastatin therapy at a dose of 20 mg daily did not prevent POAF in patients undergoing elective CABG and was associated with an increased risk of postoperative acute kidney injury (Zheng et al., 2016). The results of this trial are inconsistent with the previous studies. It could be explained by short duration of preoperative treatment, which
might have decreased the pleiotropic effects of statin therapy (Barakat et al., 2016).

One of the factors which could influence the beneficial effect of preoperative statin therapy on POAF is the duration of statin therapy. Some studies have suggested that statins reveal their full pleiotropic effect in 14 days of treatment (Barakat et al., 2016a). Meta-regression analysis indicated that preoperative statin use was associated with a 3% reduction in the risk of POAF per day of therapy (Chen et al., 2010).

Conclusions

Until now, the strongest evidence for AF prevention by statin therapy is in post-cardiac surgery patients. Recently published studies on the use of statins against AF is the duration of statin therapy. Some studies have suggested that statins reveal their full pleiotropic effect in 14 days of treatment (Barakat et al., 2016). The effect of statin on postoperative AF might depend on many factors including type of statin and dosage. The difference in impact of different types and doses of statins on AF is not fully clear. Statin therapy is recommended to be started approximately 14 days before surgery (Elgendy et al., 2015).

References


